A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease
Year: 2018
Type: conference-abstract
Source: Blood
Authors: Jacob Laubach, Andrew J Yee, Jacalyn Rosenblatt, Jeffrey V Matous, Charles M. Farber, Thomas H. Openshaw, Rodrigo O. Maegawa, Michaela L. Tsai, Irene M. Ghobrial, Giada Bianchi, Bhupendra Rawal, Heidi Dipietro, Kristen Cummings, John Harran, Peter O'Gorman, Kathleen Scott, Kathleen Fitzpatrick, Jennifer Abovich, Hannah Baker, Alexandra Savell, Joshua Hansen, Paul Richardson
Institutions: Harvard University, Dana-Farber Cancer Institute, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Colorado Blood Cancer Institute, Summit Medical Group (United States), Eastern Maine Medical Center, Eastern Maine Healthcare Systems, Mater Misericordiae University Hospital, Cancer Trials Ireland
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2907695945